APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032

29 December 2025209 pages

Choose your research edition.

Industry ResearchLong-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA and Evive Biotech, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, projected growth trends, production technology, application and end-user industry.

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company

Amgen

Mylan

Kashiv BioSciences

Pfizer

Fresenius Kabi

Coherus BioSciences

Sandoz

Italfarmaco SpA

Evive Biotech

Chugai Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Amoytop Biotech

Qilu Pharmaceutical

CSPC Baike Biopharma

SL Pharm

Lunan Pharmaceutical

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Lenograstim

Pegfilgrastim

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Hospital and Clinic

Pharmacy

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Lenograstim Major Manufacturers Table 3. Pegfilgrastim Major Manufacturers Table 4. Other Major Manufacturers Table 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital and Clinic Major Manufacturers Table 7. Pharmacy Major Manufacturers Table 8. Other Major Manufacturers Table 9. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends Table 10. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers Table 11. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges Table 12. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints Table 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2026) Table 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2027-2032) Table 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (K Units) Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032) & (K Units) Table 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026) Table 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2027-2032) Table 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021-2026) Table 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers, Product Type & Application Table 31. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026) Table 38. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2027-2032) Table 39. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 41. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 42. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026) Table 43. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2027-2032) Table 44. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2026) & (US$/Unit) Table 45. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2027-2032) & (US$/Unit) Table 46. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2026) Table 50. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2027-2032) Table 51. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 53. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 54. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026) Table 55. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2027-2032) Table 56. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2026) & (US$/Unit) Table 57. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2027-2032) & (US$/Unit) Table 58. Amgen Company Information Table 59. Amgen Business Overview Table 60. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 62. Amgen Recent Development Table 63. Mylan Company Information Table 64. Mylan Business Overview Table 65. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 67. Mylan Recent Development Table 68. Kashiv BioSciences Company Information Table 69. Kashiv BioSciences Business Overview Table 70. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 72. Kashiv BioSciences Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 77. Pfizer Recent Development Table 78. Fresenius Kabi Company Information Table 79. Fresenius Kabi Business Overview Table 80. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 82. Fresenius Kabi Recent Development Table 83. Coherus BioSciences Company Information Table 84. Coherus BioSciences Business Overview Table 85. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 87. Coherus BioSciences Recent Development Table 88. Sandoz Company Information Table 89. Sandoz Business Overview Table 90. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 92. Sandoz Recent Development Table 93. Italfarmaco SpA Company Information Table 94. Italfarmaco SpA Business Overview Table 95. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 97. Italfarmaco SpA Recent Development Table 98. Evive Biotech Company Information Table 99. Evive Biotech Business Overview Table 100. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 102. Evive Biotech Recent Development Table 103. Chugai Pharmaceutical Company Information Table 104. Chugai Pharmaceutical Business Overview Table 105. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 107. Chugai Pharmaceutical Recent Development Table 108. Jiangsu Hengrui Pharmaceuticals Company Information Table 109. Jiangsu Hengrui Pharmaceuticals Business Overview Table 110. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 112. Jiangsu Hengrui Pharmaceuticals Recent Development Table 113. Amoytop Biotech Company Information Table 114. Amoytop Biotech Business Overview Table 115. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 117. Amoytop Biotech Recent Development Table 118. Qilu Pharmaceutical Company Information Table 119. Qilu Pharmaceutical Business Overview Table 120. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 122. Qilu Pharmaceutical Recent Development Table 123. CSPC Baike Biopharma Company Information Table 124. CSPC Baike Biopharma Business Overview Table 125. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 127. CSPC Baike Biopharma Recent Development Table 128. SL Pharm Company Information Table 129. SL Pharm Business Overview Table 130. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 132. SL Pharm Recent Development Table 133. Lunan Pharmaceutical Company Information Table 134. Lunan Pharmaceutical Business Overview Table 135. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 137. Lunan Pharmaceutical Recent Development Table 138. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 139. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 140. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 141. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 142. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2021-2026) & (US$/Unit) Table 143. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2027-2032) & (US$/Unit) Table 144. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 145. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 146. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 147. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 148. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2021-2026) & (US$/Unit) Table 149. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2027-2032) & (US$/Unit) Table 150. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 152. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 153. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 154. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 155. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 156. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2021-2026) & (US$/Unit) Table 157. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2027-2032) & (US$/Unit) Table 158. United States Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 159. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 160. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 161. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 162. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 163. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 164. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 165. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2021-2026) & (US$/Unit) Table 166. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2027-2032) & (US$/Unit) Table 167. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 168. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 169. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 170. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 171. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2021-2026) & (US$/Unit) Table 172. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2027-2032) & (US$/Unit) Table 173. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 177. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 178. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 179. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2021-2026) & (US$/Unit) Table 180. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2027-2032) & (US$/Unit) Table 181. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 182. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 183. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 184. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 185. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 186. Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 187. Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 188. Switzerland Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 189. Sweden Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 190. Poland Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 191. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 192. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 193. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 194. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 195. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2021-2026) & (US$/Unit) Table 196. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2027-2032) & (US$/Unit) Table 197. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 198. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 199. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 200. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 201. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2021-2026) & (US$/Unit) Table 202. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2027-2032) & (US$/Unit) Table 203. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 204. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 205. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 206. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 207. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2021-2026) & (US$/Unit) Table 208. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2027-2032) & (US$/Unit) Table 209. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 210. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 211. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 212. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 213. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2021-2026) & (US$/Unit) Table 214. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2027-2032) & (US$/Unit) Table 215. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 216. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 217. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 218. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 219. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 220. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 221. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2021-2026) & (US$/Unit) Table 222. Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2027-2032) & (US$/Unit) Table 223. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 224. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 225. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 226. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 227. Taiwan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 228. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 229. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 230. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 231. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 232. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 233. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2021-2026) & (US$/Unit) Table 234. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Type (2027-2032) & (US$/Unit) Table 235. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 236. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 237. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 238. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 239. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2021-2026) & (US$/Unit) Table 240. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Application (2027-2032) & (US$/Unit) Table 241. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 242. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 243. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 244. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 245. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 246. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 247. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2021-2026) & (US$/Unit) Table 248. SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Country (2027-2032) & (US$/Unit) Table 249. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 250. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 251. Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 252. Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 253. Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 254. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 255. Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 256. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 257. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 258. Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 259. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Table 260. Key Raw Materials Table 261. Raw Materials Key Suppliers Table 262. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List Table 263. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers List Table 264. Research Programs/Design for This Report Table 265. Authors List of This Report Table 266. Secondary Sources Table 267. Primary Sources List of Figures Figure 1. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Image Figure 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Lenograstim Image Figure 5. Pegfilgrastim Image Figure 6. Other Image Figure 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital and Clinic Image Figure 10. Pharmacy Image Figure 11. Other Image Figure 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2032) Figure 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032) & (K Units) Figure 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales YoY (2021-2032) & (K Units) Figure 21. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales YoY (2021-2032) & (K Units) Figure 22. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales YoY (2021-2032) & (K Units) Figure 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032) Figure 31. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021 VS 2025 VS 203

Scope & coverage.

Types
  • Lenograstim
  • Pegfilgrastim
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Amgen
  • Mylan
  • Kashiv BioSciences
  • Pfizer
  • Fresenius Kabi
  • Coherus BioSciences
  • Sandoz
  • Italfarmaco SpA
  • Evive Biotech
  • Chugai Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • CSPC Baike Biopharma
  • SL Pharm
  • Lunan Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
  3. 1.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Lenograstim
  5. 1.2.3 Pegfilgrastim
  6. 1.2.4 Other
  7. 1.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
  8. 1.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital and Clinic
  10. 1.3.3 Pharmacy
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
  1. 2.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
  2. 2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
  3. 2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
  4. 2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region
  3. 3.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026)
  5. 3.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032)
  6. 3.2.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region
  9. 3.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026)
  11. 3.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032)
  12. 3.4.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers
  2. 4.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers
  6. 4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers, Product Type & Application
  13. 4.7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market CR5 and HHI
  16. 4.8.2 2025 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Tier 1, Tier 2, and Tier 3
5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
  1. 5.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type
  2. 5.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type
  6. 5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type
6 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
  1. 6.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application
  2. 6.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application
  6. 6.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application
7 Company Profiles
  1. 7.1 Amgen
  2. 7.1.1 Amgen Company Information
  3. 7.1.2 Amgen Business Overview
  4. 7.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  6. 7.1.5 Amgen Recent Developments
  7. 7.2 Mylan
  8. 7.2.1 Mylan Company Information
  9. 7.2.2 Mylan Business Overview
  10. 7.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  12. 7.2.5 Mylan Recent Developments
  13. 7.3 Kashiv BioSciences
  14. 7.3.1 Kashiv BioSciences Company Information
  15. 7.3.2 Kashiv BioSciences Business Overview
  16. 7.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  18. 7.3.5 Kashiv BioSciences Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 Fresenius Kabi
  26. 7.5.1 Fresenius Kabi Company Information
  27. 7.5.2 Fresenius Kabi Business Overview
  28. 7.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  30. 7.5.5 Fresenius Kabi Recent Developments
  31. 7.6 Coherus BioSciences
  32. 7.6.1 Coherus BioSciences Company Information
  33. 7.6.2 Coherus BioSciences Business Overview
  34. 7.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  36. 7.6.5 Coherus BioSciences Recent Developments
  37. 7.7 Sandoz
  38. 7.7.1 Sandoz Company Information
  39. 7.7.2 Sandoz Business Overview
  40. 7.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  42. 7.7.5 Sandoz Recent Developments
  43. 7.8 Italfarmaco SpA
  44. 7.8.1 Italfarmaco SpA Company Information
  45. 7.8.2 Italfarmaco SpA Business Overview
  46. 7.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  48. 7.8.5 Italfarmaco SpA Recent Developments
  49. 7.9 Evive Biotech
  50. 7.9.1 Evive Biotech Company Information
  51. 7.9.2 Evive Biotech Business Overview
  52. 7.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  54. 7.9.5 Evive Biotech Recent Developments
  55. 7.10 Chugai Pharmaceutical
  56. 7.10.1 Chugai Pharmaceutical Company Information
  57. 7.10.2 Chugai Pharmaceutical Business Overview
  58. 7.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  60. 7.10.5 Chugai Pharmaceutical Recent Developments
  61. 7.11 Jiangsu Hengrui Pharmaceuticals
  62. 7.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 7.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 7.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  66. 7.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 7.12 Amoytop Biotech
  68. 7.12.1 Amoytop Biotech Company Information
  69. 7.12.2 Amoytop Biotech Business Overview
  70. 7.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  72. 7.12.5 Amoytop Biotech Recent Developments
  73. 7.13 Qilu Pharmaceutical
  74. 7.13.1 Qilu Pharmaceutical Company Information
  75. 7.13.2 Qilu Pharmaceutical Business Overview
  76. 7.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  78. 7.13.5 Qilu Pharmaceutical Recent Developments
  79. 7.14 CSPC Baike Biopharma
  80. 7.14.1 CSPC Baike Biopharma Company Information
  81. 7.14.2 CSPC Baike Biopharma Business Overview
  82. 7.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  84. 7.14.5 CSPC Baike Biopharma Recent Developments
  85. 7.15 SL Pharm
  86. 7.15.1 SL Pharm Company Information
  87. 7.15.2 SL Pharm Business Overview
  88. 7.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  90. 7.15.5 SL Pharm Recent Developments
  91. 7.16 Lunan Pharmaceutical
  92. 7.16.1 Lunan Pharmaceutical Company Information
  93. 7.16.2 Lunan Pharmaceutical Business Overview
  94. 7.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  96. 7.16.5 Lunan Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
  2. 8.1.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  3. 8.1.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  4. 8.1.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2032)
  5. 8.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
  6. 8.2.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  7. 8.2.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  8. 8.2.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2032)
  9. 8.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
  10. 8.3.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
  2. 9.1.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  4. 9.1.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2032)
  5. 9.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
  6. 9.2.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  8. 9.2.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2032)
  9. 9.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
  10. 9.3.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
  2. 10.1.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  3. 10.1.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  4. 10.1.3 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2032)
  5. 10.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
  6. 10.2.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  7. 10.2.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  8. 10.2.3 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
  2. 11.1.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  4. 11.1.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2032)
  5. 11.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
  6. 11.2.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  8. 11.2.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2032)
  9. 11.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
  10. 11.3.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
  2. 12.1.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2032)
  5. 12.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
  6. 12.2.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2032)
  9. 12.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
  10. 12.3.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
  2. 13.1.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process
  6. 13.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
  9. 13.2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst